Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries

Modern Pathology

Volumn 20, Issue 10, 2007, Pages 1078-1084

  Zhang, Zhihong ^a,b   Singh, Meenakshi ^c   Davidson, Susan ^c   Rosen, Daniel G ^a   Yang, Gong ^a   Liu, Jinsong ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

BRCA heterozygous mutation; BTAK; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN; PROTEIN BTAK; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; CELL CULTURE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM CELL; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; OVARIECTOMY; OVARY; OVARY CANCER; OVARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STATISTICAL SIGNIFICANCE; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; PRECANCEROUS CONDITIONS; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 34548716437     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800945     Document Type: Article

References (51)

1. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995;72:805-812.
2. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005;19:2925-2940.
3. Shah N, Lepre J, Tu Y, et al. Can we identify cellular pathways implicated in cancer using gene expression data? Proc IEEE Comput Soc Bioinform Conf 2003;2:94-103.
4. Somasundaram K, MacLachlan TK, Burns TF, et al. BRCA1 signals ARF-dependent stabilization and co-activation of p53. Oncogene 1999;18:6605-6614.
5. Chai YL, Cui J, Shao N, et al. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene 1999;18:263-268.
6. MacLachlan TK, Dash BC, Dicker DT, et al. Repression of BRCA1 through a feedback loop involving p53. J Biol Chem 2000;275:31869-31875.
7. Gowen LC, Avrutskaya AV, Latour AM, et al. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009-1012.
8. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3:389-395.
9. Daniels MJ, Wang Y, Lee M, et al. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 2004;306:876-879.
10. Salazar H, Godwin AK, Daly MB, et al Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810-1820.
11. Barakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000;89:383-390.
12. Schlosshauer PW, Cohen CJ, Penault-Llorca F, et al. Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer 2003;98:2599-2606.
13. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metast Rev 2003;22:451-464.
14. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004;14:29-36.
15. Stenoien DL, Sen S, Mancini MA, et al. Dynamic association of a tumor amplified kinase, Aurora-A, with the centrosome and mitotic spindle. Cell Motil Cytoskeleton 2003;55:134-146.
16. Marumoto T, Hirota T, Morisaki T, et al. Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 2002;7:1173-1182.
17. Giet R, Petretti C, Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol 2005;15:241-250.
18. Hu W, Kavanagh JJ, Deaver M, et al. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res 2005;15:49-57.
19. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-193.
20. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-3065.
21. Sakakura C, Hagiwara A, Yasuoka R, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001;84:824-831.
22. Ouchi M, Fujiuchi N, Sasai K, et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004;279:19643-19648.
23. Hsu LC, Doan TP, White RL. Identification of a gamma-tubulin-binding domain in BRCA1. Cancer Res 2001;61:7713-7718.
24. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999;22:37-43.
25. Rosen DG, Yang G, Bast Jr RC, et al. Use of ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol 2005;407:660-676.
26. Rosen DG, Yang G, Deavers MT, et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006;106:1925-1932.
27. Stratton JF, Buckley CH, Lowe D, et al. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J Natl Cancer Inst 1999;91:626-628.
28. Casey MJ, Bewtra C, Hoehne LL, et al. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol Oncol 2000;78:278-287.
29. Piek JM, Verheijen RH, Menko FH, et al. Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. Histopathology 2003;43:26-32.
30. Qi Cai K, Klein-Szanto A, Karthik D, et al. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecol Oncol 2006;103:719-728.
31. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-1289.
32. Deligdisch L, Gil J, Kerner H, et al. Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer 1999;86:1544-1550.
33. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18(Suppl 2):S19-S32.
34. Dyck HG, Hamilton TC, Godwin AK, et al. Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer 1996;69:429-436.
35. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000;18:2728-2732.
36. Werness BA, Afify AM, Bielat KL, et al. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 1999;30:151-157.
37. Roland IH, Yang WL, Yang DH, et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer 2003;98:2607-2623.
38. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-288.
39. Kruk PA, Godwin AK, Hamilton TC, et al. Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. Gynecol Oncol 1999;73:229-236.
40. He QY, Zhou Y, Wong E, et al. Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies. Gynecol Oncol 2005;98:68-76.
41. Hirota T, Kunitoku N, Sasayama T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585-598.
42. Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997;14:2195-2200.
43. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000;6:1833-1839.
44. Okada S, Ouchi T. Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. J Biol Chem 2003;278:2015-2020.
45. Andrews PD, Knatko E, Moore WJ, et al. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003;15:672-683.
46. Gritsko TM, Coppola D, Paciga JE, et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003;9:1420-1426.
47. Goepfert TM, Adigun YE, Zhong L, et al. Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res 2002;62:4115-4122.
48. Morgan SE, Kastan MB. p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 1997;71:1-25.
49. Wang X, Zhou YX, Qiao W, et al. Overexpression of aurora kinase a in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006;25:7148-7158.
50. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005;65:2899-2905.
51. Vankayalapati H, Bearss DJ, Saldanha JW, et al. Targeting aurora 2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther 2003;2:283-294.